amarin
reports
third
quarter
financial
results
provides
business
update
total
revenue
increased
third
quarter
first
nine
months
compared
periods
despite
headwinds
progress
continues
towards
icosapent
ethyl
approval
commercialization
europe
management
host
conference
call
today
et
dublin
ireland
bridgewater
globe
newswire
amarin
corporation
plc
nasdaq
amrn
today
announced
financial
results
three
nine
months
ended
september
provided
update
company
operations
key
achievements
third
quarter
recent
weeks
achieved
record
quarterly
revenue
levels
reported
million
net
total
revenue
third
quarter
increase
compared
third
quarter
resulting
net
total
revenue
first
nine
months
million
increase
compared
period
reported
million
net
total
revenue
third
quarter
increase
compared
third
quarter
resulting
net
total
revenue
first
nine
months
million
increase
compared
period
reaffirmed
strategy
continue
increasing
promotion
vascepa
reported
court
appeals
federal
circuit
upheld
march
district
court
ruling
favor
two
generic
companies
connection
abbreviated
new
drug
applications
andas
related
vascepa
capsules
initial
triglyceride
lowering
indication
generic
competition
could
potentially
launch
united
states
time
amarin
continues
expect
enhanced
education
promotional
initiatives
opportunity
meaningfully
grow
revenue
vascepa
united
states
incremental
initiatives
include
advertisement
launched
new
cardiovascular
risk
reduction
indication
third
quarter
promotion
builds
important
outreach
healthcare
professionals
made
direct
sales
team
size
doubled
near
start
amarin
strategy
initiatives
expand
market
despite
likely
generic
competition
reflect
large
number
patients
could
potentially
benefit
vascepa
survey
data
indicating
healthcare
professionals
patients
yet
aware
benefits
vascepa
cardiovascular
risk
reduction
indication
launched
early
amarin
decision
continue
invest
expanding
market
vascepa
also
reflects
confidence
manufacturing
processes
company
built
decade
achieve
consistent
stable
supply
support
anticipated
global
demand
reported
court
appeals
federal
circuit
upheld
march
district
court
ruling
favor
two
generic
companies
connection
abbreviated
new
drug
applications
andas
related
vascepa
capsules
initial
triglyceride
lowering
indication
generic
competition
could
potentially
launch
united
states
time
amarin
continues
expect
enhanced
education
promotional
initiatives
opportunity
meaningfully
grow
revenue
vascepa
united
states
incremental
initiatives
include
advertisement
launched
new
cardiovascular
risk
reduction
indication
third
quarter
promotion
builds
important
outreach
healthcare
professionals
made
direct
sales
team
size
doubled
near
start
amarin
strategy
initiatives
expand
market
despite
likely
generic
competition
reflect
large
number
patients
could
potentially
benefit
vascepa
survey
data
indicating
healthcare
professionals
patients
yet
aware
benefits
vascepa
cardiovascular
risk
reduction
indication
launched
early
amarin
decision
continue
invest
expanding
market
vascepa
also
reflects
confidence
manufacturing
processes
company
built
decade
achieve
consistent
stable
supply
support
anticipated
global
demand
progressed
european
regulatory
review
commercial
preparations
continued
support
regulatory
review
vascepa
european
medicines
agency
ema
expectation
early
approval
vascepa
commercial
sale
europe
process
hiring
select
people
extensive
commercial
experience
europe
preparing
market
access
negotiations
continued
support
regulatory
review
vascepa
european
medicines
agency
ema
expectation
early
approval
vascepa
commercial
sale
europe
process
hiring
select
people
extensive
commercial
experience
europe
preparing
market
access
negotiations
expanded
edical
society
recommendations
support
efficacy
safety
vascepa
european
society
cardiology
expanded
guidelines
recommend
use
vascepa
treating
acute
coronary
syndrome
patients
previously
recommended
use
vascepa
treating
patients
established
cardiovascular
disease
european
society
cardiology
expanded
guidelines
recommend
use
vascepa
treating
acute
coronary
syndrome
patients
previously
recommended
use
vascepa
treating
patients
established
cardiovascular
disease
reported
dditional
vascepa
clinical
results
data
define
vascepa
multifactorial
mechanisms
action
clinical
need
effects
reducing
cardiovascular
risk
evaporate
study
results
reported
august
showed
reduction
coronary
plaque
months
patients
established
coronary
plaque
pci
results
presented
october
showed
post
hoc
subgroup
analyses
patients
study
stenting
bypass
forms
percutaneous
cardiovascular
intervention
pci
experienced
significantly
reduced
rates
ischemic
events
treated
vascepa
renal
results
presented
october
showed
prespecified
post
hoc
subgroup
analyses
patients
study
compromised
renal
function
baseline
prior
treatment
vascepa
placebo
experienced
higher
rates
cardiovascular
events
overall
population
studied
additionally
vascepa
use
treatment
patients
baseline
decreased
renal
function
resulted
similarly
favorable
relative
risk
reductions
numerically
greater
absolute
risk
reductions
versus
placebo
comparison
overall
patient
population
evaporate
study
results
reported
august
showed
reduction
coronary
plaque
months
patients
established
coronary
plaque
pci
results
presented
october
showed
post
hoc
subgroup
analyses
patients
study
stenting
bypass
forms
percutaneous
cardiovascular
intervention
pci
experienced
significantly
reduced
rates
ischemic
events
treated
vascepa
renal
results
presented
october
showed
prespecified
post
hoc
subgroup
analyses
patients
study
compromised
renal
function
baseline
prior
treatment
vascepa
placebo
experienced
higher
rates
cardiovascular
events
overall
population
studied
additionally
vascepa
use
treatment
patients
baseline
decreased
renal
function
resulted
similarly
favorable
relative
risk
reductions
numerically
greater
absolute
risk
reductions
versus
placebo
comparison
overall
patient
population
reaffirmed
c
linical
trial
results
study
vascepa
china
expected
year
end
assuming
positive
results
study
conducted
amarin
commercial
partner
vascepa
china
regulatory
submission
china
could
follow
promptly
thereafter
assuming
positive
results
study
conducted
amarin
commercial
partner
vascepa
china
regulatory
submission
china
could
follow
promptly
thereafter
advanced
e
nrollment
three
related
pilot
studies
clinical
studies
vascepa
argentina
canada
united
states
reported
substantial
patient
enrollment
studies
amarin
supports
manage
clinical
data
collected
studies
blinded
final
results
studies
expected
available
time
mechanistic
data
continues
provide
reasons
believe
vascepa
could
potentially
beneficial
lessen
impact
clinical
studies
vascepa
argentina
canada
united
states
reported
substantial
patient
enrollment
studies
amarin
supports
manage
clinical
data
collected
studies
blinded
final
results
studies
expected
available
time
mechanistic
data
continues
provide
reasons
believe
vascepa
could
potentially
beneficial
lessen
impact
maintained
trong
cash
balance
reduced
debt
september
amarin
reported
total
cash
investments
million
million
remaining
debt
instrument
amarin
plans
pay
full
fourth
quarter
management
commentary
third
quarter
productive
challenging
quarter
amarin
total
net
revenue
grew
record
levels
reflecting
increased
prescription
levels
vascepa
despite
many
patients
yet
returning
doctors
offices
preventative
healthcare
due
global
pandemic
stated
john
thero
president
chief
executive
officer
believe
key
court
decisions
regarding
vascepa
patents
related
triglyceride
lowering
indication
wrong
plan
continue
pursue
matter
highest
level
moreover
believe
numerous
factors
including
vascepa
recently
launched
first
drug
cardiovascular
risk
reduction
indication
continued
investment
justified
market
expansion
expectation
increased
revenue
profit
accumulate
amarin
remain
focused
bringing
potentially
drug
patients
united
states
europe
elsewhere
excited
nearing
ema
regulatory
decision
vascepa
busy
preparing
anticipated
commercial
launch
europe
large
growing
opportunity
amarin
bring
proven
effective
therapy
millions
patients
high
risk
cardiovascular
events
launching
major
markets
europe
allows
us
create
greatest
value
amarin
would
share
profits
partner
importantly
leverage
knowledge
experience
gained
tremendous
progress
made
commercial
team
coming
months
expect
achieve
number
key
milestones
including
topline
data
readout
phase
clinical
trial
vascepa
china
partner
eddingpharm
recommendation
committee
medicinal
products
human
use
chmp
relating
european
regulatory
review
approval
process
presentation
numerous
data
support
vascepa
cardiovascular
risk
reduction
indication
upcoming
annual
scientific
sessions
american
heart
association
added
thero
prescription
growth
normalized
prescriptions
vascepa
prescription
grams
vascepa
representing
supply
increased
approximately
third
quarter
compared
period
based
data
symphony
health
iqvia
respectively
estimated
normalized
vascepa
prescriptions
based
data
symphony
health
iqvia
totaled
approximately
third
quarter
year
date
estimated
normalized
prescriptions
vascepa
increased
approximately
compared
first
nine
months
based
data
symphony
health
iqvia
respectively
estimated
normalized
vascepa
prescriptions
based
data
symphony
health
iqvia
totaled
approximately
first
nine
months
respectively
much
pharmaceutical
industry
vascepa
revenue
prescription
growth
adversely
impacted
pandemic
amarin
temporarily
suspended
promotional
activities
march
beginning
june
phased
approach
resumed
interactions
healthcare
providers
extent
healthcare
providers
allow
recently
substantially
sales
force
personnel
permitted
resume
interaction
done
manner
consistent
guidelines
local
state
government
health
officials
united
states
although
permission
may
restricted
geographies
continue
experience
resurgence
pandemic
due
various
state
local
shelter
place
travel
restrictions
reports
iqvia
indicated
patient
visits
medical
offices
april
approximately
compared
levels
similarly
iqvia
reported
significant
drop
number
routine
lab
tests
including
blood
tests
conducted
physicians
typically
require
office
visits
including
physical
examinations
blood
tests
prior
prescribing
new
medications
vascepa
commencing
september
weekly
normalized
prescriptions
reached
levels
consistent
slightly
higher
levels
according
iqvia
data
september
number
patient
visits
health
care
providers
increased
meaningfully
lows
april
remained
volume
levels
reported
prior
impact
began
significantly
affect
united
states
amarin
optimistic
worst
period
impact
levels
patients
seeking
ordinary
course
doctor
visits
lab
tests
may
behind
amarin
expects
however
dynamic
continue
unfavorable
impact
revenue
least
near
term
accordingly
degree
timing
potential
reacceleration
vascepa
revenue
growth
uncertain
particularly
resurgences
spread
infection
various
geographies
reinforcement
social
distancing
protocols
amarin
field
team
continues
utilize
necessary
various
means
interact
healthcare
professionals
virtually
interactions
tend
less
frequent
potentially
less
impactful
communications
particularly
case
vascepa
newly
introduced
many
healthcare
professionals
treatment
cardiovascular
risk
reduction
based
second
fda
indication
launched
january
increasing
promotion
united
states
augment
amarin
ongoing
activities
educate
healthcare
professionals
parallel
sales
team
getting
back
field
amarin
launched
first
ever
campaign
focused
use
vascepa
cardiovascular
risk
reduction
indicated
patients
campaign
highlights
persistent
cardiovascular
risk
benefit
vascepa
reduce
risk
heart
attack
stroke
added
statin
campaign
intended
raise
awareness
vascepa
among
healthcare
professionals
consumers
encourages
patients
ask
providers
vascepa
healthcare
professionals
patients
learn
vascepa
amarin
anticipates
expanded
vascepa
prescriptions
revenue
however
timing
magnitude
increases
remain
difficult
predict
due
challenges
quantifying
pace
stability
recovery
unprecedented
nature
limited
history
vascepa
approved
indication
financial
update
net
total
revenue
three
nine
months
ended
september
million
million
respectively
compared
million
million
corresponding
periods
respectively
indicating
increases
respectively
net
product
revenue
three
nine
months
ended
september
million
million
respectively
compared
million
million
corresponding
periods
respectively
indicating
increases
respectively
increase
net
product
revenue
driven
primarily
increased
volume
vascepa
sales
customers
united
states
well
modest
increase
vascepa
net
selling
price
united
states
reflecting
various
factors
including
managed
care
coverage
improvements
increase
also
driven
vascepa
sales
outside
united
states
approximately
million
million
three
nine
months
ended
september
compared
nil
million
three
nine
months
ended
september
primarily
result
initial
order
first
half
ensure
adequate
product
supply
amarin
commercial
partner
launch
vascepa
canada
recognized
upon
shipment
amarin
partner
addition
amarin
recognized
licensing
royalty
revenue
approximately
million
million
three
nine
months
ended
september
respectively
agreements
commercialization
vascepa
outside
united
states
compares
licensing
royalty
revenue
million
million
periods
respectively
cost
goods
sold
three
nine
months
ended
september
million
million
respectively
compared
million
million
corresponding
periods
respectively
amarin
overall
gross
margin
net
product
revenue
three
nine
months
ended
september
respectively
compared
three
nine
months
ended
increase
gross
margin
net
product
sales
driven
gross
margin
product
sales
three
nine
months
ended
september
partially
offset
gross
margin
product
sales
amarin
partners
outside
united
states
contractual
agreements
generally
sell
product
basis
licensing
royalty
revenue
separately
recorded
selling
general
administrative
sg
expense
three
nine
months
ended
september
million
million
respectively
compared
million
million
respectively
corresponding
periods
representing
increases
increase
primarily
due
personnel
costs
related
sales
force
expansion
well
increase
promotional
activity
following
launch
vascepa
including
promotion
augmented
july
amarin
launched
first
television
advertisement
vascepa
focused
cardiovascular
risk
reduction
based
product
new
label
research
development
r
expense
three
nine
months
ended
september
million
million
respectively
compared
million
million
respectively
corresponding
periods
representing
increases
respectively
increase
expense
primarily
driven
costs
beyond
conduct
study
analyze
samples
collected
patients
well
costs
associated
achievement
certain
milestones
amarin
strategic
collaboration
agreement
mochida
costs
support
various
publications
pilot
studies
gaap
amarin
reported
net
loss
million
three
months
ended
september
basic
diluted
loss
per
share
included
million
compensation
expense
comparison
amarin
reported
net
loss
million
third
quarter
basic
diluted
loss
per
share
included
million
compensation
expense
gaap
amarin
reported
net
loss
million
nine
months
ended
september
basic
diluted
loss
per
share
included
million
compensation
expense
comparison
amarin
reported
net
loss
million
basic
diluted
loss
per
share
nine
months
ended
september
included
million
compensation
expense
excluding
gains
losses
compensation
adjusted
net
income
million
third
quarter
adjusted
basic
diluted
earnings
per
share
compared
adjusted
net
income
million
third
quarter
adjusted
basic
diluted
earnings
per
share
excluding
gains
losses
compensation
adjusted
net
income
million
nine
months
ended
september
adjusted
basic
diluted
earnings
per
share
compared
adjusted
net
loss
million
nine
months
ended
september
adjusted
basic
diluted
loss
per
share
september
amarin
reported
aggregate
cash
investments
million
consisting
cash
cash
equivalents
million
liquid
investments
million
respectively
september
amarin
reported
million
net
accounts
receivable
million
gross
accounts
receivable
allowances
reserves
million
inventory
amarin
plans
pay
remaining
million
debt
fourth
quarter
repaid
amarin
debt
obligations
previously
expressed
uncertainties
regarding
effects
duration
pandemic
scope
potential
generic
competition
better
understood
amarin
providing
estimate
expected
revenue
results
based
current
plans
expectations
amarin
believes
current
capital
resources
sufficient
achieve
sustained
positive
cash
flows
vascepa
including
commercial
launch
vascepa
europe
results
anticipated
vary
significantly
quarterly
basis
including
likely
negative
net
cash
flow
periods
factors
expected
contribute
variability
include
cost
response
amarin
educational
promotional
initiatives
advance
launch
united
states
vascepa
new
cardiovascular
risk
reduction
indication
continued
varied
impact
pandemic
amarin
business
society
potential
launch
generic
versions
vascepa
united
states
cost
response
amarin
efforts
toward
development
launch
vascepa
europe
amarin
believes
adequate
supply
support
likely
sales
demand
company
intends
continue
purchase
supply
needed
support
anticipated
vascepa
growth
united
states
globally
september
amarin
approximately
million
american
depository
shares
adss
ordinary
shares
outstanding
million
common
share
equivalents
series
convertible
preferred
shares
outstanding
approximately
million
equivalent
shares
underlying
stock
options
exercise
price
million
equivalent
shares
underlying
restricted
deferred
stock
units
conference
call
webcast
information
amarin
host
conference
call
november
et
discuss
information
conference
call
heard
live
investor
relations
section
company
website
via
telephone
dialing
within
united
states
outside
united
states
replay
call
made
available
period
two
weeks
following
conference
call
hear
replay
call
dial
pin
replay
call
also
available
company
website
shortly
call
use
adjusted
financial
information
included
press
release
adjusted
financial
information
defined
securities
exchange
commission
regulation
gaap
financial
measure
directly
comparable
adjusted
financial
measure
used
discussed
reconciliation
differences
adjusted
financial
measure
comparable
gaap
financial
measure
included
press
release
condensed
consolidated
financial
statements
adjusted
net
income
loss
derived
taking
gaap
net
income
loss
adjusting
compensation
expense
management
uses
adjusted
financial
measures
internal
reporting
forecasting
purposes
publicly
providing
business
outlook
evaluate
company
performance
evaluate
compensate
company
executives
company
provided
financial
measures
addition
gaap
financial
results
believes
adjusted
financial
measures
provide
investors
better
understanding
company
historical
results
core
business
operations
management
believes
adjusted
financial
measures
provide
useful
supplemental
information
investors
regarding
underlying
performance
company
business
operations
investors
reminded
consider
measures
addition
substitute
financial
performance
measures
prepared
accordance
gaap
measures
limitations
reflect
amounts
associated
company
results
operations
determined
accordance
gaap
addition
noted
financial
measures
may
different
measures
used
companies
management
may
utilize
measures
illustrate
performance
future
amarin
amarin
corporation
plc
rapidly
growing
innovative
pharmaceutical
company
focused
developing
commercializing
therapeutics
improve
cardiovascular
health
amarin
lead
product
icosapent
ethyl
available
prescription
united
states
canada
lebanon
united
arab
emirates
vascepa
yet
approved
available
countries
amarin
together
commercial
partners
select
geographies
pursuing
additional
regulatory
approvals
vascepa
china
europe
middle
east
information
amarin
visit
cardiovascular
risk
number
deaths
united
states
attributed
cardiovascular
disease
continues
rise
new
recurrent
heart
attacks
per
year
approximately
every
seconds
united
states
stroke
rates
per
year
approximately
every
seconds
accounting
every
deaths
cardiovascular
disease
results
deaths
per
year
united
aggregate
million
major
adverse
cardiovascular
events
per
year
cardiovascular
disease
average
one
every
seconds
united
states
alone
controlling
bad
cholesterol
also
known
one
way
reduce
patient
risk
cardiovascular
events
heart
attack
stroke
death
however
even
achievement
target
levels
millions
patients
still
significant
persistent
risk
cardiovascular
events
especially
patients
elevated
triglycerides
statin
therapy
shown
control
thereby
reducing
risk
cardiovascular
events
significant
cardiovascular
risk
remains
statin
therapy
people
elevated
triglycerides
cardiovascular
events
compared
people
normal
range
triglycerides
taking
global
cardiovascular
outcomes
study
designed
evaluate
effect
vascepa
adult
patients
controlled
mg
dl
median
baseline
mg
dl
statin
therapy
various
cardiovascular
risk
factors
including
persistent
elevated
triglycerides
mg
dl
median
baseline
mg
dl
either
established
cardiovascular
disease
secondary
prevention
cohort
diabetes
mellitus
least
one
cardiovascular
risk
factor
primary
prevention
cohort
conducted
seven
years
completed
followed
patients
clinical
sites
countries
largest
number
sites
located
within
united
states
conducted
based
special
protocol
assessment
agreement
fda
design
study
published
march
clinical
primary
results
published
new
england
journal
medicine
november
total
events
results
published
journal
american
college
cardiology
march
publications
found
r
section
company
website
icosapent
ethyl
capsules
vascepa
icosapent
ethyl
capsules
prescription
treatment
approved
fda
comprised
solely
active
ingredient
icosapent
ethyl
ipe
unique
form
eicosapentaenoic
acid
vascepa
initially
launched
united
states
based
drug
initial
fda
approved
indication
use
adjunct
therapy
diet
reduce
triglyceride
levels
adult
patients
severe
mg
dl
hypertriglyceridemia
since
launch
vascepa
prescribed
eight
million
times
vascepa
covered
major
medical
insurance
plans
new
cardiovascular
risk
indication
vascepa
approved
fda
december
indications
limitation
use
vascepa
indicated
adjunct
maximally
tolerated
statin
therapy
reduce
risk
myocardial
infarction
stroke
coronary
revascularization
unstable
angina
requiring
hospitalization
adult
patients
elevated
triglyceride
tg
levels
mg
dl
established
cardiovascular
disease
diabetes
mellitus
two
additional
risk
factors
cardiovascular
disease
adjunct
diet
reduce
tg
levels
adult
patients
severe
mg
dl
hypertriglyceridemia
effect
vascepa
risk
pancreatitis
patients
severe
hypertriglyceridemia
determined
important
safety
information
vascepa
contraindicated
patients
known
hypersensitivity
anaphylactic
reaction
vascepa
components
vascepa
associated
increased
risk
vs
atrial
fibrillation
atrial
flutter
requiring
hospitalization
trial
incidence
atrial
fibrillation
greater
patients
previous
history
atrial
fibrillation
atrial
flutter
known
whether
patients
allergies
fish
shellfish
increased
risk
allergic
reaction
vascepa
patients
allergies
discontinue
vascepa
reactions
occur
vascepa
associated
increased
risk
vs
bleeding
trial
incidence
bleeding
greater
patients
receiving
concomitant
antithrombotic
medications
aspirin
clopidogrel
warfarin
common
adverse
reactions
cardiovascular
outcomes
trial
incidence
frequent
placebo
musculoskeletal
pain
vs
peripheral
edema
vs
constipation
vs
gout
vs
atrial
fibrillation
vs
common
adverse
reactions
hypertriglyceridemia
trials
incidence
frequent
placebo
arthralgia
vs
oropharyngeal
pain
vs
frequent
placebo
arthralgia
vs
oropharyngeal
pain
vs
adverse
events
may
reported
calling
fda
patients
receiving
vascepa
concomitant
anticoagulants
agents
monitored
bleeding
key
clinical
effects
vascepa
major
adverse
cardiovascular
events
included
clinical
studies
section
prescribing
information
vascepa
set
forth
effect
vascepa
time
first
occurrence
cardiovascular
events
patients
elevated
triglyceride
levels
risk
factors
cardiovascular
disease
vascepa
placebo
vascepa
vs
placebo
n
n
incidence
rate
per
patient
years
n
n
incidence
rate
per
patient
years
hazard
ratio
ci
primary
composite
endpoint
cardiovascular
death
myocardial
infarction
stroke
coronary
revascularization
hospitalization
unstable
angina
mace
key
secondary
composite
endpoint
cardiovascular
death
myocardial
infarction
stroke
mace
secondary
endpoints
fatal
myocardial
infarction
emergent
urgent
coronary
revascularization
cardiovascular
death
hospitalization
unstable
angina
fatal
stroke
includes
adjudicated
cardiovascular
deaths
deaths
undetermined
causality
determined
caused
myocardial
ischemia
invasive
testing
requiring
emergent
hospitalization
full
vascepa
prescribing
information
found
statements
press
release
contains
statements
including
expectations
regarding
financial
metrics
performance
prescription
growth
revenue
growth
operating
expenses
inventory
purchases
managed
care
coverage
vascepa
including
impact
pandemic
outcome
patent
litigation
launch
generic
competition
metrics
timing
outcome
regulatory
reviews
recommendations
approvals
related
reimbursement
decisions
china
europe
elsewhere
timing
outcome
clinical
trial
china
timing
outcome
amarin
decision
launch
vascepa
directly
major
markets
europe
partner
potentially
markets
europe
timing
outcome
amarin
patent
litigation
efforts
timing
outcome
promotion
activities
including
campaigns
education
healthcare
professionals
commercial
international
expansion
prescription
growth
revenue
growth
future
revenue
levels
including
contributions
recently
hired
sales
representatives
sufficiency
current
capital
resources
achieve
sustained
positive
cash
flows
ability
commercial
supply
generic
companies
amarin
creditworthiness
largest
customers
expectations
related
exclusivity
various
jurisdictions
ongoing
patent
litigation
appeal
efforts
associated
business
plans
various
scenarios
impact
pandemic
forgoing
statements
promises
guarantees
involve
substantial
risks
uncertainties
amarin
ability
effectively
commercialize
vascepa
depend
part
ability
continue
effectively
finance
business
efforts
third
parties
ability
create
market
demand
vascepa
education
marketing
sales
activities
achieve
broad
market
acceptance
vascepa
receive
adequate
levels
reimbursement
payers
develop
maintain
consistent
source
commercial
supply
competitive
price
comply
legal
regulatory
requirements
connection
sale
promotion
vascepa
secure
maintain
patent
protection
vascepa
among
factors
could
cause
actual
results
differ
materially
described
projected
herein
include
following
uncertainties
associated
generally
research
development
clinical
trials
related
regulatory
approvals
risk
sales
may
meet
expectations
related
cost
may
increase
beyond
expectations
risk
patents
may
determined
infringed
valid
patent
litigation
applications
may
result
issued
patents
sufficient
protect
vascepa
franchise
list
description
risks
uncertainties
risks
associated
investment
amarin
found
amarin
filings
securities
exchange
commission
including
recent
quarterly
report
form
existing
prospective
investors
cautioned
place
undue
reliance
statements
speak
date
hereof
amarin
undertakes
obligation
update
revise
information
contained
press
release
whether
result
new
information
future
events
circumstances
otherwise
amarin
statements
reflect
potential
impact
significant
transactions
company
may
enter
mergers
acquisitions
dispositions
joint
ventures
material
agreements
amarin
may
enter
amend
terminate
availability
information
amarin
investors
others
note
amarin
communicates
investors
public
using
company
website
investor
relations
website
including
limited
investor
presentations
investor
faqs
securities
exchange
commission
filings
press
releases
public
conference
calls
webcasts
information
amarin
posts
channels
websites
could
deemed
material
information
result
amarin
encourages
investors
media
others
interested
amarin
review
information
posted
channels
including
investor
relations
website
regular
basis
list
channels
may
updated
time
time
amarin
investor
relations
website
may
include
social
media
channels
contents
amarin
website
channels
website
may
accessed
website
channels
shall
deemed
incorporated
reference
filing
securities
act
amarin
contact
information
investor
inquiries
elisabeth
schwartz
investor
relations
amarin
corporation
plc
ir
investor
inquiries
lee
stern
solebury
trout
lstern
media
inquiries
alina
kolomeyer
communications
amarin
corporation
plc
pr
media
inquiries
consolidated
balance
sheet
data
gaap
unaudited
september
december
thousands
assets
current
assets
cash
cash
equivalents
restricted
cash
investments
accounts
receivable
net
inventory
prepaid
current
assets
total
current
assets
property
plant
equipment
net
investments
operating
lease
asset
assets
intangible
asset
net
total
assets
liabilities
stockholders
equity
current
liabilities
accounts
payable
accrued
expenses
current
liabilities
debt
instrument
deferred
revenue
current
total
current
liabilities
liabilities
deferred
revenue
operating
lease
liability
liabilities
total
liabilities
stockholders
equity
preferred
stock
common
stock
additional
capital
treasury
stock
accumulated
deficit
total
stockholders
equity
total
liabilities
stockholders
equity
consolidated
statements
operations
data
gaap
unaudited
three
months
ended
september
nine
months
ended
september
thousands
except
per
share
amounts
thousands
except
per
share
amounts
product
revenue
net
licensing
royalty
revenue
total
revenue
net
less
cost
goods
sold
gross
margin
operating
expenses
selling
general
administrative
research
development
total
operating
expenses
operating
loss
interest
income
net
income
expense
net
loss
operations
taxes
income
tax
provision
benefit
net
loss
loss
per
share
basic
diluted
weighted
average
shares
basic
diluted
excluding
compensation
selling
general
administrative
expenses
three
months
ended
september
respectively
research
development
expenses
respectively
periods
reconciliation
net
income
loss
unaudited
three
months
ended
september
nine
months
ended
september
thousands
except
per
share
amounts
thousands
except
per
share
amounts
net
loss
gaap
compensation
expense
adjusted
net
income
loss
diluted
earnings
loss
per
share
basic
diluted
weighted
average
shares
basic
diluted
references
american
heart
association
heart
disease
stroke
update
report
american
heart
association
circulation
ganda
op
bhatt
dl
mason
rp
et
al
unmet
need
adjunctive
dyslipidemia
therapy
hypertriglyceridemia
management
j
coll
cardiol
budoff
triglycerides
lipoproteins
causal
pathway
cardiovascular
disease
j
cardiol
toth
pp
granowitz
c
hull
et
al
high
triglycerides
associated
increased
cardiovascular
events
medical
costs
resource
use
administrative
claims
analysis
patients
high
residual
cardiovascular
risk
j
heart
assoc
nordestgaard
bg
lipoproteins
atherosclerotic
cardiovascular
disease
new
insights
epidemiology
genetics
biology
circ
res
bhatt
dl
steg
pg
brinton
e
et
behalf
investigators
rationale
design
reduction
cardiovascular
events
icosapent
trial
clin
cardiol
bhatt
dl
steg
pg
miller
et
behalf
investigators
cardiovascular
risk
reduction
icosapent
ethyl
hypertriglyceridemia
n
engl
j
med
bhatt
dl
steg
pg
miller
et
behalf
investigators
reduction
first
total
ischemic
events
icosapent
ethyl
across
baseline
triglyceride
tertiles
j
coll
cardiol
